Farnesyl Thiosalicylic Acid Amide
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
IC50: 20 and 10 μM for the growth of PANC-1 and U87 tumor cells, respectively
Farnesyl thiosalicylic acid amide (FTS-A), an farnesyl thiosalicylic acid derivative, inhibits tumor growth.
Farnesylthiosalicylic acid (FTS, Salirasib), a Ras inhibitor, can interfer with Ras membrane interactions that are crucial for Ras-dependent transformation.
In vitro: Previous study examined the effects of the FTS-A and its two analogs (FTS-MA and FTS-DMA) on panc-1 and U87 cells and the results showed that all three FTS-amides caused a dose-dependent decrease in cell number of both cell lines exhibiting similar potencies. Cell death was observed at concentrations higher than 50 μM. The IC50s recorded in both cell lines were at the range of 10-20 μM. FTS-A, FTS-MA, and FTS-DMA caused a clear decrease in the levels of K-Ras-GTP in Panc-1 cells and in U87 cells. Reduction in the level of N-Ras-GTP was observed only in U87 cells and no effect on H-Ras-GTP was observed in either cell line [1].
In vivo: The effect of FTS-A on brain tumor growth was examined using a nude mouse model with human glioblastoma U87 cells intracranially implanted into the striatum area. FTS-A at 100 mg/kg was administered orally twice daily. Results showed that the increase in tumor volume recorded over time in the FTS-A treated mouse was significantly lower than that recorded in the control mouse. Moreover, it was found that more contrast agent molecules accumulated in the control mice as compared to the FTS-A treated mice. In addition, this study did not see any inflammatory response in the brains of the controls or in the brains of FTS-A-treated mice [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Goldberg, L. ,Haklai, R.,Bauer, V., et al. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: Farnesylthiosalicylamide inhibits tumor growth in nude mice models. Journal of Medicinal Chemistry 52, 197-205 (2009).
Physical Appearance | A solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. |
Storage | Store at -20°C |
M.Wt | 357.6 |
Cas No. | 1092521-74-8 |
Formula | C22H31NOS |
Synonyms | FTS Amide,Salirasib Amide |
Solubility | ≤10mg/ml in DMSO;10mg/ml in dimethyl formamide |
Chemical Name | 2-[[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]thio]-benzamide |
SDF | Download SDF |
Canonical SMILES | C\C(CC/C=C(CC/C=C(C)\C)\C)=C/CSC1=C(C(N)=O)C=CC=C1 |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Quality Control & MSDS
- View current batch:
-
Purity ≥ 96.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)